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ABSTRACT
Since 1986, the pharmacological management
of pain was mainly based on the WHO
‘‘analgesic ladder’’, with very few drugs
available. The huge development of the basic
knowledge on pain and its therapy, especially in
the past 15 years, has made the ‘‘guidelines’’ of
WHO obsolete. That’s why, during the
presidency of EFIC of one of the authors (GV),
an international advisory board was proposed to
review the document, but mainly to ameliorate
the approach to the pain patients.
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EDITORIAL
In 2009, an international board of distinguished
pain specialists was established in order to
address the pervasive unmet worldwide
problem of inadequate control of pain. Called
CHANGE PAIN, the organization’s 21 founding
members consisted of key opinion leaders,
representing the United States of America and
various countries in Europe. The European Pain
Federation EFIC (formerly The European
Federation of International Association for the
Study of Pain Chapters) and a corporate sponsor
supported the efforts of the group, which meets
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twice yearly under the chairmanship of the
President of EFIC.
WHERE WE’VE BEEN
Pain control, particularly for chronic
non-cancer pain, has historically been a major
unmet need in medicine, even in the world’s
most advanced healthcare systems. When
CHANGE PAIN first convened, it was the
consensus that some of the main reasons for
inadequate analgesia were related to: failure to
balance adequate analgesia with tolerability,
which leads to poor patient compliance and
discontinuation of treatment; neuropathic pain
is prevalent and challenging to treat, because of
the lack of fully efficacious drugs; and
inadequate physician–patient communication
about pain, which leads to suboptimal
treatment goals [1]. In an effort to improve
this situation, the board recommended that
clinicians gain a better understanding of pain
mechanisms and the emerging knowledge
about the multifactorial nature of chronic
pain, in order that those pharmacologic
decisions could be better based on the
underlying mechanistic factors. The board also
recommended techniques to improve
communications between chronic pain
patients and their healthcare providers.
Additionally, the board explored the concept
of the ‘vicious circle’ of pharmacologic therapy
in chronic pain patients, in which drug doses
are alternately increased to provide adequate
analgesia and decreased to reduce side effects
[2, 3].
The first international expert meeting of
CHANGE PAIN was held in June 2010 in
Rome, Italy. Presentations were made about
current pain control status to the more than 200
international pain specialist attendees. As
delineated at the meeting, the strategy of
CHANGE PAIN is to implement clinically
meaningful changes that will lead to better
pain control. Among its efforts to achieve this
goal, CHANGE PAIN set out to conduct research
about chronic pain, to publish informative and
educational papers about pain, and to develop
and promote continuing medical education
(CME) activities related to the application of
evidence-based strategies for improving pain
management.
A physician survey conducted by the
CHANGE PAIN initiative in 2009 revealed that
while most physicians agreed that pain control
and improved quality of life were treatment
goals for their pain patients, most believed that
the medical community had limited knowledge
about recent research on basic science of pain,
such as the differences between nociceptive and
neuropathic pain [2]. The group also developed
a simple CHANGE PAIN Scale to help clinicians
to better record pain intensity, define treatment
goals for the individual patient, and provide
ways to improve the patient’s quality of life [2].
In November 2010, CHANGE PAIN evaluated
evidence in order to move toward a prognostic
approach to defining chronic pain by including
psychological, behavioral, and other
dimensions, such as physical changes, in order
to modernize the existing pain models.
Previously, the definition of chronic pain was
problematic in that it defined chronic pain only
temporally (e.g., persisting for 3 months or
longer), even though the duration does not
account for the differences between chronic and
acute pain in terms of pathophysiology,
physiology, mechanistic aspects, or
biopsychosocial factors. A scoring system has
now been developed to help define whether a
patient dealing with persistent pain has
probable or possible chronic pain [4].
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In June 2011, CHANGE PAIN convened in
Belgium and reviewed the mechanisms and
knowledge base about chronic pain and its
treatment options. Issues in chronic pain
diagnosis, the availability and efficacy of
multimodal pharmacological therapies, and a
biopsychosocial approach to chronic pain
treatment were presented. A multidisciplinary
team approach to chronic pain management
was advocated, which would involve a primary
care physician, pharmacist, physiotherapist,
nurse, and psychologist or psychiatrist, and
supplemented for some patients with
neurologists, rheumatologists, orthopedists, or
other specialists, to be led by a pain specialist or
anesthesiologist. The successes of nine such
multidisciplinary centers for chronic pain care
in Europe since 2005 were reviewed [5].
Later that same year, the CHANGE PAIN
advisory board met to discuss the special issues
related to pain treatment in the geriatric
population. Although chronic pain is
prevalent among the elderly, it is often
untreated or under-treated [6]. Pain control
can be complicated by other age-related
physiological changes, increasing rates of
polypharmacy and comorbidities, and
generally poor pain medication adherence
rates among the elderly [7, 8]. CHANGE PAIN
challenged the two common misconceptions
about pain in the elderly: first, that older people
have a diminished capacity to feel pain and,
second, that pain is an unavoidable part of
growing older that cannot be treated. Pain in
senior patients can be treated, but dosing needs
to be adjusted to account for the decline of
organ function with age (particularly the liver
for drugs metabolized through CYP pathways).
CHANGE PAIN recognized that a subset of
geriatric pain patients with dementia,
Alzheimer’s disease, and other forms of
cognitive impairment are often difficult to
recognize and diagnose. Therefore, special pain
scales were sought for assessing pain in such
patients. In this regard, the board was
introduced to the PainvisionTM system being
developed in Belgium in which the facial
expressions of such patients are continuously
monitored in real time and compared to
computer-based standards to correlate facial
expressions with pain levels.
In March 2012, the CHANGE PAIN Advisory
Board convened to discuss the topic of cancer
pain management. As more cancer patients
survive and live longer, pain control in cancer
survivor care is becoming an increasingly
important clinical concern. Cancer pain is
often multifactorial in nature, often including
a neuropathic component, and may be
complicated by disease progression as well as
the chemotherapeutic therapies themselves.
Cancer pain may be intermittent or
continuous and is often punctuated by
‘breakthrough pain’ (flares of severe pain
against a background of baseline pain). Despite
the fact that most cancer patients experience
pain [9], 22 % said they were never asked about
pain or offered pain control and 11 % took no
analgesics at all for cancer pain (including
over-the-counter products) [9]. Overall, cancer
pain is not routinely managed by referrals to
pain specialists. Indeed, the disheartening
picture of cancer pain treatment in 2016
demonstrates that the very same obstacles that
confronted colleagues 20 years ago confront us
today. Cancer pain is not routinely assessed,
rarely if ever discussed frankly, and may not be
prioritized in treatment plans that focus more
on disease than on pain control. Cancer
patients may hesitate to ‘distract’ their
oncologists by bringing up pain symptoms
while others may assume that pain is an
inevitable part of cancer and that nothing can
be done to alleviate it. Moreover, some patients
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may deliberately conceal their pain from their
medical team, afraid that worsening pain might
indicate disease progression and a poor
prognosis [10]. Some patients are categorically
opposed to opioid pain relievers and may prefer
to suffer in silence rather than risk having a
doctor recommend these drugs [11].
CHANGE PAIN suggests some simple
guidance: cancer patients should have a
validated pain assessment at every follow-up
session, the clinical team should discuss pain
with the patient during each and every session,
and the oncologist should develop a plan to
address the pain using evidence-based
treatments, and refer the patient to a pain
specialist if necessary [12].
WHERE WE ARE TODAY
Pain remains a largely unmet need. However, an
increasing number of professional publications
and presentations, patient advocacy groups,
and public awareness point toward the need
for appropriate analgesia and are raising
awareness that inadequate pain control is an
important and urgent problem, in which
clinicians and healthcare systems can make
meaningful improvements in many patients’
quality of life with a few conscientiously
applied, evidence-based steps.
The first step involves a thorough knowledge
among physicians and other caregivers about
analgesic agents and the use of evidence to
guide their appropriate selection, use, and
avoidance of misuse or abuse. A significant
barrier to more effective pain relief continues to
be a reluctance or concern to prescribe opioid
analgesics. In many parts of the world, opioid
use is virtually nonexistent, even for the
treatment of severe to very severe pain at end
of life [13, 14]. Even in nations where opioids
are more readily available and accepted, some
prescribers may hesitate to utilize them, even
when they are medically appropriate, for fear of
fueling opioid misuse and abuse or concern
about legal liability [15]. This reluctance to treat
the pain of the majority exists despite the fact
that only a subset of patients prescribed opioids
will ever take then inappropriately [16]. Many
clinicians also feel that they are not adequately
equipped to manage complex pain conditions
or are inadequately trained to prescribe opioid
analgesics. These problems are pervasive and
unnecessarily contribute to inadequate pain
treatment, but they can be addressed by open,
frank, and objective recognition of the
problems and by informed knowledge about
the emerging knowledge and options in
analgesic pharmacotherapy and the available
clinical guidelines. Continuous effort needs to
be placed on continuing educational activities
for each of the healthcare specialties,
presentations, meetings, and educational
outreach and collaboration with patient
advocacy groups, researchers, and regulatory
groups.
The CHANGE PAIN Advisory board
continues to meet twice a year to address
these key topics and The Advisory Board key
opinion leaders publish and speak about these
important topics all over the world.
WHERE WE’RE GOING
The populations of many nations are aging,
which means there will be a marked increase in
chronic pain conditions in the coming decades.
In addition, breakthroughs in oncology and
other specialties means that many patients will
be living longer with ‘managed’ diseases and
many of them will have concomitant painful
symptoms. It is unclear how the healthcare
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systems of the world will manage the
anticipated increase in the number of pain
patients. New perspectives appear at the
horizon, especially if we better examine the
physiopathological mechanisms of chronic
pain that appear very much correlated to all
the cells of the central nervous system (CNS),
including glia, and not just to neurons [8]. This
would also open the possibility of different
pharmacological approaches [17, 18]. Moreover,
there is a continuing need for more and better
clinical education, more research into pain
mechanisms, and more targeted
pharmacological options to help address
specific and challenging types of pain.
Patient education is also needed to help
patients overcome counterproductive personal,
familial, and cultural attitudes about pain and
suffering. These attitudes include beliefs that
pain is inevitable or that taking pain relievers is
a sign of weakness. Some patients may feel that
discussing pain symptoms is the same as
complaining and could be taken as a sign of
moral weakness. Other patients resist pain
management therapies for fear of becoming
addicted, or in the mistaken belief that pain
relievers should only be taken to help manage
the most severe levels of pain. Some may believe
that taking opioid pain relievers will be
detrimental to their self-image, reputation, or
keeping their jobs. Healthcare providers can go
a long way to dispel many of these maladaptive
beliefs about pain control, but patient-based
educational efforts are needed as well. Patients
must also be educated in the appropriate use of
analgesic agents so that the medications are
taken exactly as prescribed and neither
discontinued abruptly nor doubled-up on bad
days. The proper disposal of unused analgesic
medications is another important concern that
needs to be addressed. CHANGE PAIN intends
to be on the forefront of these issues.
Prescribers must balance safety with efficacy
when selecting analgesic medications. This is
especially important for drugs with toxicity
issues (such as potential organ toxicity
associated with NSAIDs and liver toxicity
associated with acetaminophen) and the
adverse events (such as respiratory depression,
sedation, and other opioid-associated side
effect) as well as abuse potential associated
with opioids. Patients need to be made aware
of the benefits and risks of each of the categories
and each of the analgesic medications they are
prescribed. For patients at risk of opioid misuse
and abuse, there are tools to assess individual
risk factors [19, 20] (e.g., the Universal
Precautions in opioid prescribing [21, 22]) and
guidelines for treatment. Another measure is
abuse-deterrent formulations (ADF) of opioid
agents, designed to prevent or resist tampering.
National and local efforts in the form of
prescription drug monitoring programs
(PDMPs) and laws imposing strict penalties
directed at ‘pill mills’ should be supported.
Just as many painful conditions are
multifactorial and are best addressed using a
multimodal therapeutic approach, the public
health problem of opioid misuse and abuse is a
complex one that requires a multimodal
approach. Efforts by CHANGE PAIN will be
directed toward emphasizing and publicizing
the importance of balancing opioid analgesia
with safety. Prescribers need better education
about opioid analgesia and patients, the public,
the media, and regulatory, legislative, and
judicial bodies must be made aware of both
the risks and benefits of opioid therapy.
CHANGE PAIN will promote interactions in
which all parties will feel comfortable to be
involved in cooperative collaborations.
In summary, the goals of CHANGE PAIN
remain the same, and as important, as they were
half a decade ago: to provide a measure of relief
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for those suffering from pain, through
education, basic and clinical research, and
communication. This is no easy task. Attaining
these goals will continue to require the
professional stamina, determination, and
persistence demonstrated in the past years.
However, considering the profound benefits
that can be realized, the goal of better and
safer pain control is worth our greatest efforts.
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